STATEMENT OF NEED
Hematopoietic stem cell transplant (HSCT) is a potentially curative therapy for patients with hematologic malignancies. There are 2 primary types of HSCT: autologous, where the cells are taken from the patient, and allogeneic, where the cells come from a matched sibling donor or an unrelated donor. Advances in HSCT include the introduction of reduced-intensity conditioning regimens that allow HSCT in older patients and alternative graft sources that afford a donor for nearly all patients who require a transplant. Despite these advances, studies continue to show that the use of HSCT remains suboptimal, placing many patients at increased risk for poor survival outcomes.
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of cancer patients eligible for hematopoietic stem cell transplant.
Upon completion of this activity, participants should be able to:
- Differentiate patient selection criteria for younger versus older HSCT candidates
- Apply emerging and evolving data on HSCT in treatment planning for patients with hematologic malignancies
- Assess strategies to manage transplant-related complications so that patients may achieve the optimal HSCT outcomes
Sergio A. Giralt, MD (Chairperson)
Chief, Adult Bone Marrow Transplant Service
Memorial Sloan Kettering Cancer Center
David A. Rizzieri, MD
Professor of Medicine
Duke Cancer Institute
Daniel Weisdorf, MD
Professor of Medicine
University of Minnesota
Steven Devine, MD
Professor of Internal Medicine
The Ohio State University
Mark R. Litzow, MD
Professor of Medicine
There is no fee to participate in or claim CME credit for this activity.
Please note that the University of Cincinnati and i3 Health do not accept responsibility for travel, accommodation, or any other costs incurred by registrants in the rare event that this activity should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation.
Jointly Provided by
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Cincinnati and i3 Health. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
A conflict of interest is created when individuals in a position to control the content of CE have a relevant financial relationship with a commercial interest which, therefore, may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits. The University of Cincinnati will identify, review and resolve all conflicts of interest that speakers, authors or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. The University of Cincinnati does not endorse any products or services.
Sergio A. Giralt, MD discloses that he has served on the advisory board for Amgen, Celgene, Jazz Pharmaceuticals, Kite Pharma, Novartis, Sanofi, and Takeda. He has received grants/reseach support from Janssen Pharmaceuticals, Miltenyi Biotec, Sanofi, and Takeda.
David A. Rizzieri, MD discloses that he has served on the advisory board for Agios, Celgene, Daiichi-Sankyo, Inc., Gilead, Incyte, Novartis, Pfizer, Seattle Genetics, Spectrum Pharmaceuticals, and Teva Pharmaceutical Industries, Ltd. He has served on the speakers bureau for Gilead, Incyte, Seattle Genetics, and Spectrum Pharmaceuticals. He has served as a consultant for Daiichi-Sankyo, Inc.
Daniel Weisdorf, MD discloses that he has served as a consultant for AbGenomics International, Inc., CSL Behring, Incyte, and Seattle Genetics. He has received grants/research support from Alexion and Incyte.
Steven Devine, MD has no relevant financial relationships to disclose.
Mark R. Litzow, MD discloses that he has received grants/research support from Actinium Pharmaceuticals, Inc.
University of Cincinnati staff members, i3 Health staff members, and the peer/content reviewer for this activity have no relevant financial relationships to disclose.
Disclosures are on file at the University of Cincinnati, Office of Continuing Medical Education.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must submit a completed evaluation at the end of the activity.
UNAPPROVED USE DISCLOSURE
The University of Cincinnati and i3 Health require CME/CE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
The information provided at this CME/CE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.
This activity is supported by an independent educational grant from Incyte Corporation and Otsuka America Pharmaceutical, Inc.